iX Biopharma Ltd
Company Profile
Business description
iX Biopharma Ltd is a Singapore-based specialty pharmaceutical and nutraceutical company focused on the development, manufacture, and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. Its products under development are Wafermine and BnoX for pain management, Wafesil for erectile dysfunction, WafeRest for improved sleep quality, and others. Its business segments are the Specialty Pharmaceutical and Nutraceutical business segments. The firm's business segments operate in the United States of America, Singapore, Australia, and China, of which the majority of the revenue comes from the United States of America. The company generates the majority of its revenue from the sale of specialty pharmaceutical products.
Contact
1 Kim Seng Promenade
No. 14-01
Great World City East Lobby
Singapore237994
SGPT: +65 62352270
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
30 June 2027
Employees
51
Stocks News & Analysis
stocks
Chart of the Week: China demand for copper falls amidst record rally
stocks
Reporting season was stronger than share prices suggest
stocks
How Anthropic makes money—and what investors should know ahead of its IPO filing
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,160.30 | 13.70 | -0.15% |
| CAC 40 | 8,280.63 | 21.22 | -0.26% |
| DAX 40 | 25,839.33 | 130.78 | -0.50% |
| Dow JONES (US) | 53,061.95 | 295.07 | 0.56% |
| FTSE 100 | 10,756.45 | 32.83 | -0.30% |
| HKSE | 25,311.21 | 18.52 | -0.07% |
| NASDAQ | 26,217.83 | 118.05 | 0.45% |
| Nikkei 225 | 64,325.64 | 1,889.70 | -2.85% |
| NZX 50 Index | 13,926.35 | 4.22 | -0.03% |
| S&P 500 | 7,666.60 | 35.13 | 0.46% |
| S&P/ASX 200 | 8,978.40 | 1.80 | -0.02% |
| SSE Composite Index | 3,941.39 | 38.50 | -0.97% |